

HAND DELIVERED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE

Date of Deposit: November 21, 2001

5

Our Case No. 21726/92990

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
APPLICATION FOR UNITED STATES LETTERS PATENT

10 INVENTORS: WILLIAM R. LAW

TITLE: USE OF ADENOSINE DEAMINASE INHIBITORS TO
TREAT SYSTEMIC INFLAMMATORY RESPONSE
SYNDROME

15

ATTORNEY: ALICE O. MARTIN
BARNES & THORNBURG
2600 CHASE PLAZA
10 SOUTH LASALLE STREET
20 CHICAGO, ILLINOIS 60603
(312) 357-1313

09694923 1201
T0827 E264660

USE OF ADENOSINE DEAMINASE INHIBITORS TO TREAT SYSTEMIC INFLAMMATORY RESPONSE SYNDROME

Inventor: William R. Law

5 This application claims priority to co-pending PCT/US00/13987, filed May 22,
2000.

10 This invention relates to a new use of adenosine deaminase inhibitors in the
prevention or treatment of adverse consequences of systemic inflammatory responses
(SIRS). These conditions are ameliorated by increasing the local concentration of
adenosine in affected regions.

BACKGROUND OF THE INVENTION

15 Conditions resulting in or from a systemic inflammatory response syndrome
(SIRS) are associated with an exaggerated immune response, oxygen free-radical-
mediated injury, and tissue perfusion maldistribution. Such conditions include endotoxin
shock, septic shock, sepsis, endotoxemia, septicemia, peritonitis, and adult respiratory
distress syndrome (ARDS). Current treatment is unsatisfactory. Therapeutic attempts
to modify cytokine responses during SIRS-related conditions have focussed on antibodies
to the cytokines or cytokine receptor antagonists. These approaches have proven
unsuccessful because some level of cytokine response is required for survival from SIRS-
20 related conditions.

Adenosine has been reported to be an endogenous modulator of inflammation by
virtue of its effects on stimulated granulocyte function (Cronstein *et al.*, 1986) and on
macrophage, lymphocyte and platelet function. Adenosine receptor agonists have been
reported to be beneficial in an experimental model of inflammation (Schrier *et al.*, 1990).
25 Adenosine and a related analog have been reported to inhibit in vitro production of the
cytokine, tumor necrosis factor α (Parmely *et al.*, 1991). Antibodies to TNF- α have not
been shown to alter mortality in sepsis (Abraham *et al.*, 1998; Cohen *et al.*, 1996; and
Amiot *et al.*, 1997).

Adenosine is an endogenous, ubiquitous molecule that modulates immune
30 function, can suppress or increase free-radical production, and produces vasodilation in
regions wherein adenosine is produced in significant quantities.

03694923 112301

Adenosine has a short half life (<1 sec) in human blood (Moser *et al.*, 1989), and therefore high doses of adenosine would need to be administered continuously to achieve effective treatment levels. Adenosine has been reported to exhibit negative inotropic, chronotropic and dromotropic effects (Belardinelli *et al.*, 1989) and to cause coronary steal by preferentially dilating vessels in nonischemic regions. Consequently, high doses of adenosine are toxic and this toxicity severely limits its therapeutic potential. However, by increasing adenosine concentration locally, i.e. at the target site within the target tissue, the beneficial effects of adenosine might be provided without the toxic systemic effects.

Riches *et al.* (1985) reported that adenosine inhibited β -galactosidase secretion from zymosan particle-stimulated mouse peritoneal macrophages. The adenosine nucleotides ATP, ADP, and AMP were also effective inhibitors, but only after hydrolysis to adenosine. These authors found that the inhibitory effect of adenosine *in vitro* could be increased with erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), a potent inhibitor of adenosine deaminase. By thus inhibiting adenosine breakdown to inosine and hypoxanthine the inhibitory effects of adenosine were prolonged. Similarly, Itoh *et al.* (1989) reported that both adenosine and 1-methyladenosine inhibited chemiluminescence by zymosan-stimulated mouse peritoneal macrophages *in vitro*.

Adenosine has been shown to inhibit TNF- α produced in response to endotoxin (LPS). Using LPS, Eigler *et al.* (1997) stimulated isolated human peripheral blood mononuclear cell production of TNF- α . The addition of adenosine deaminase (increasing endogenous adenosine degradation) or an adenosine A₂ receptor antagonist further increased TNF- α production, while an adenosine A₁ receptor antagonist had no effect. This indicated that *endogenous* adenosine production after stimulation with LPS served to limit the TNF- α response of the monocyte. Eigler *et al.* (1997) further demonstrated that TNF- α production by LPS-stimulated monocytes could be inhibited by dipyridamole, an agent that prevents cellular adenosine reuptake a major pathway for adenosine removal by monocytes (Barankiewicz, 1985). Adenosine-modulated TNF- α production by other cell types has also been shown. Cronstein *et al.* (1995) examined leukocyte accumulation and TNF- α production in skin air pouches injected with carrageenan. Endogenous adenosine concentrations were altered by inhibiting adenosine kinase, an enzyme contributing to nucleotide salvage via phosphorylation of adenosine. Pre-treatment of

rats with oral GP-1-515, an adenosine kinase inhibitor (*reducing* adenosine salvage into nucleotides), reduced leukocyte accumulation and TNF- α production. TNF- α concentration in the pouch exudates were reduced from 1518 pg/ml to 780 pg/ml. The direct involvement of adenosine in this response was proven by reversing the inhibitory effects of GP-1-515 with either excess exogenous adenosine deaminase or an adenosine A₂ receptor antagonist. An adenosine kinase inhibitor, GP-1-515, produced by Gensia Inc., is reported to elevate local adenosine concentrations in tissues.

Adenosine deaminase (ADA) is a cytosolic and membrane-bound enzyme which catalyzes the deamination of adenosine to inosine, a necessary step prior to entry of adenosine catabolites into the xanthine oxidase pathway to form uric acid. Inhibition of adenosine deaminase can reduce the rate at which extracellular adenosine is degraded, leading to increased adenosine outside of the cell where it is pharmacologically active. Inhibition of ADA has such an effect. In isolated guinea pig hearts addition of the adenosine deaminase inhibitor, EHNA, to the perfusion medium, in the presence of 5'-amino-5'-deoxyadenosine to inhibit phosphorylation of adenosine to AMP, was reported to result in a 15-fold increase of adenosine release (Schrader, 1983). These effects were not apparent in the absence of ADA inhibition.

Gruber *et al.* (WO94/17809) teaches that >98% inhibition of ADA results in immunosuppression (pg 2, ln 28-33). This publication further specifies that for the treatment described to be safe and effective, inhibition of ADA cannot exceed 95% or 98% (pg 7, ln 10-13; pg 8, lns 21-25; Claims 2&3, 19&20, 37&38).

As Gruber *et al.* teaches, sepsis, and similar named conditions (page 8, ln 21-25), involve an inflammatory response which results from localized infection with one of a number of organisms, including gram negative and positive bacteria, viruses, mycobacteria, fungi, yeast, and worms (page 9, ln 35-37; page 9, ln 1). This is consistent with the 1992 American Chest Physicians/Society of Critical Care Medicine consensus report (ACCP/SCCM report) on definitions for sepsis (Bone *et al.*, 1999). Bone *et al.* also teaches in the ACCP/SCCM report that a systemic inflammatory response syndrome (SIRS) is seen in association with a large number of clinical conditions besides those resulting from infection by organisms, as is the case with sepsis. This means that sepsis, and related conditions associated with the inflammatory response to infections, as defined

and outlined by Gruber *et al.*, can fall within the parameters of SIRS, but that SIRS is a larger set, inclusive of conditions not defined by Gruber *et al.*

Gruber *et al.* indicated a very short or prophylactic treatment for particular conditions involving an inflammatory response, listing such conditions as sepsis, 5 septicemia, septic shock, endotoxin shock, endotoxemia, meningitis, burns, adult respiratory distress syndrome, and necrotizing enterocolitis (pg. 8, lines 19 to 21; lines 22 to 25). The treatment defined by Gruber is directed specifically at an inflammatory process (page 8, lines 6-8), or thrombosis (page 7, lines 23 to 24).

In an effort to find effective treatments for SIRS and related conditions, inhibitors 10 of adenosine deaminase were explored.

SUMMARY OF THE INVENTION

The present invention is directed to novel uses of compounds which are potent and selective adenosine deaminase inhibitors. Another aspect of the present invention is directed to the clinical use of adenosine deaminase inhibitors as a method of increasing 15 adenosine concentrations in selected locations in biological systems. To treat a mammal in need thereof, an effective amount of an adenosine deaminase inhibitor is administered to the person. An "effective amount" is that dose which will ameliorate symptoms in the mammal to whom it is administered by inhibiting adenosine deaminase to 95%, 98% and up to 100% levels. In the present invention, limits on effective inhibition of ADA are not 20 set. Indeed, for the present invention, inhibition can be up to 100% and the greatest efficacy is seen when the effective dose inhibits ADA more than 98%. *In vivo* inhibition of adenosine deaminase prevents deamination of adenosine resulting in higher local concentrations of endogenous adenosine than present before treatment. As a result of the very short half-life of adenosine and very low quantities of adenosine in tissues, this 25 effect is most pronounced in regions producing the most adenosine such as ischemic regions, regions manifesting metabolic anomalies, or regions undergoing elevated adenylate cyclase activity. Hence, the beneficial effects of adenosine are enhanced in site and event specific manners and toxic systemic effects are reduced.

Adenosine deaminase inhibitors may be used clinically to treat medical conditions 30 where an increased localized adenosine concentration is beneficial. Accordingly, the present invention is directed to the prophylactic and affirmative treatment of systemic inflammatory response syndrome (SIRS) conditions benefitted by enhanced adenosine

099492 1300
"032T" E2546560

levels and as may be initiated or sustained by contributing factors such as inflammation, arthritis, autoimmune diseases, cardiac arrhythmias, ulcers and irritable bowel syndrome. In particular, the present invention is also directed to the prophylactic and affirmative treatment of SIRS associated with sepsis, septicemia (including endotoxemia), various forms of septic shock (including endotoxic shock), cardiopulmonary bypass, whole blood or blood product transfusion, or infiltration of body compartments by non-infectious foreign bodies. For example, adenosine deaminase inhibitors are useful in the prophylactic or affirmative treatment of a localized or systemic inflammatory response to infection by one or more of several types of organisms, including bacteria (gram negative or gram positive), viruses (including retroviruses), mycobacteria, yeast, protozoa or parasites. Furthermore, the present invention is directed to the treatment of disorders wherein SIRS results from non-infectious origins, such as cardiopulmonary bypass, transfusion of blood or blood products, and infiltration of body cavities or openings by non-infectious chemicals or foreign bodies. Furthermore, the present invention is directed to the treatment of disorders in which vascular leakage is involved. In particular, the present invention is directed to the treatment of burn injury.

Methods of preventing or treating adverse consequences of systemic inflammatory response syndrome (SIRS) include administering an inhibitor of adenosine deaminase, which results in increased local concentrations of adenosine in selected tissues. For the uses described herein, inhibition of adenosine deaminase can be up to 100% for periods of less than 72 hours without concern for immunosuppression. Effective dosage in this regard can be measured in bodily fluids, tissues, or dialysate within 2 hours of dosing by standard ADA assay procedures. There are no other therapeutic agents that are used in the art for the treatment of SIRS which act via inhibition of adenosine deaminase. The use of an adenosine kinase inhibitor (Firestein *et al.*, 1994) has the deleterious potential to reduce cellular nucleotide stores, and increase oxyradical-mediated damage via the degradation of the resultant increased endogenous adenosine. In contrast, an adenosine deaminase inhibitor increases local adenosine concentrations, while simultaneously preventing adenosine's entry into the xanthine oxidase pathway. Neither does it interfere with the re-phosphorylation of adenosine into cellular nucleotides. As such, the treatment of sepsis and SIRS by inhibiting adenosine deaminase amplifies regional vasodilatory and immuno-modulating effects of adenosine,

0994923-1201
FOIA b2 b6 b7C

but is superior to adenosine kinase inhibition by reducing oxygen free radical-mediated damage that occurs via the xanthine oxidase pathway, and increases the amount of adenosine available for high energy nucleotide repletion. Two advantages of inhibition of adenosine deaminase over inhibition of adenosine kinase to treat SIRS are as follows:

- 5 1. inhibition of adenosine deaminase reduces oxyradical-mediated tissue damage that occurs via adenosine breakdown through the xanthine oxidase pathway; and
2. inhibition of adenosine deaminase will not prevent maintenance of cellular high energy adenine nucleotides that occurs via adenosine kinase.

10 Therapeutic approaches of the present invention to combat the relevant physiological systems in SIRS by inhibition of adenosine deaminase are singularly targeted. Thus, the use of inhibitors of adenosine deaminase circumvent the need for multiple therapeutic approaches. This simplifies the treatment of SIRS, and is likely to be more cost effective.

15 The method of the present invention increases adenosine concentrations only in regions wherein it is produced. The regions wherein adenosine is produced during sepsis are the hepatosplanchnic and skeletal muscle regions. The method is superior to the use of adenosine analogues in that adenosine analogues exert systemic effects, having potential to cause refractory hypotension, inappropriate bradycardia, and myocardial
20 depression. An advantage of the method of the present invention is that cytokine responses are merely modulated, rather than abated.

Administration of an adenosine deaminase inhibitor such as pentostatin increases local endogenous adenosine concentrations. This leads to several important effects reflecting a balanced modulation of the body's response to inflammatory processes:
25 amplification of anti-inflammatory cytokines, such as IL-10 concomittant with attenuation of specific cytokine receptors, such as those for TNF- α , and suppression of pro-inflammatory cytokines, such as TNF- α . Increasing endogenous adenosine by this method increases tissue perfusion, independent of ischemia, in the locale wherein adenosine production is increased. Increased endogenous adenosine by this method
30 inhibits neutrophil accumulation, adhesion, and activation leading to oxygen free-radical-mediated damage of tissue in the locale wherein adenosine production is increased. Inhibition of adenosine deaminase also reduces the amount of oxygen free-radical-

099493-12301
FOIA b2 b6 b7C

mediated damage by reducing substrate flow through the xanthine oxidase metabolic pathway.

Brogden and Sorken (1993) have discussed the potential immunosuppression that may occur with prolonged inhibition of ADA activity, which may increase the incidence of infection, or exacerbate concurrent infection. This requires inhibition of ADA activity for more than 3 consecutive days, resulting in prolonged inhibition of ADA activity. The use of ADA inhibitors to treat SIRS as disclosed herein allows for up to 100% inhibition of ADA activity for brief periods, less than 3 consecutive days in order to exert effective treatment. The effective dose envisioned in this invention can be regulated by serial measurement of ADA activity in various bodily fluids, tissues, dialysates, or cells. Up to 100% inhibition of ADA activity should be achieved within 2 hours of an initial dose, with recovery of at least 50% of ADA activity within 5 days thereafter. Additional doses may be needed to achieve up to 100% inhibition within the first 24 hours.

Inhibitors suitable for practice of the invention include pentostatin, EHNA, ARADS.

In contrast to Gruber, the present invention discloses the usefulness of inhibiting adenosine deaminase throughout the course of disease, and under such conditions that are defined by a systemic inflammatory response syndrome (SIRS) agents or other foreign bodies, and systemic responses to animal venom. The more inclusive use of the term SIRS is also specific in envisioning the affirmative treatment of perfusion alterations not associated with ischemia or thrombosis, oxyradical-mediated tissue damage, and vascular leakage all occurring in tandem as the consequences (syndrome) of the inciting insult, in addition to the imbalance in responses to inflammatory reactions.

The invention of Gruber *et al.* is directed to methods of treating or preventing an inflammatory response. In contrast the present invention is directed to methods of treating or preventing the adverse consequences of SIRS. In the ACCP/SCCM report, Bone *et al.* teaches that SIRS is a systemic response to an inflammatory process, which includes progression to multiple organ dysfunctions and failures that cannot be reliably attributed to infection or inflammation. The present invention is directed toward treatment or prevention of the *consequences* of systemic inflammatory responses (the *syndrome*), rather than to the inflammatory response itself.

0094923-12204
FOR TIT "E254660

A contrast is that both oxy-radical-mediated tissue damage and perfusion maldistribution are components of the *SIRS syndrome*, but are not inflammatory responses. These differences may be made clear by drawing analogies to an uncomfortably hot house. According to the methods taught by Gruber, **less** than 95-98% inhibition of ADA is required and necessary to simply reduce the inflammatory response. This would be analogous to shutting off a furnace to cool the house. The present application discloses using up to 99% or more inhibition of ADA, such an amount of inhibition as to restore a balance to the physiological response to inflammation (not the inflammation itself), maintain or improve higher than normal regional blood flows (not ischemia), and reduce oxygen free radical-mediated damage. This would be analogous to regulating the temperature of the house by adjusting the thermostat (regulating the air conditioning and the furnace; not just shutting off the latter), opening some windows, and adding or removing insulation.

Data provided herein shows that endogenously produced adenosine during sepsis is not a response to ischemia, nor is there any pharmacological manipulation needed to increase local adenosine production during sepsis. Evidence for a lack of increased adenosine production in response to ischemia is also indicated by vascular resistance and blood flow. Ischemia-mediated increases in adenosine production results in normal to decreased blood flows to affected regions, and blockade of adenosine receptors under these conditions would cause severe reductions in blood flow (ischemia). The evidence presented in the present application indicates effective adenosine actions during sepsis in muscle and gastrointestinal structures during sepsis that were responsible for **higher** than normal blood flows. No pharmacological manipulations were used to cause this. Furthermore, the evidence presented in the present application shows that preventing the actions of adenosine, by blockade of adenosine receptors, resulted in **normal** blood flow through these regions in septic animals, rather than ischemia. Thus, effectiveness of adenosine deaminase inhibition during SIRS would be under conditions wherein adenosine production would not have to be increased by either ischemia or pharmacological manipulation as a prerequisite for effectiveness of adenosine deaminase inhibition.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the chemical structure of pentostatin where O=oxygen, H=hydrogen, N=nitrogen, C=carbon, and the bonding is shown as standard in the art.

FIG. 2 graphically presents the relation between serum tumor necrosis factor- α and sepsis over time.

FIG. 3 graphically depicts the level of TNF in liver and in spleen over time in septic and non-septic animals.

FIG. 4 graphically compares levels of serum tumor necrosis factor- α at 4 hours and 24 hours after treatment with either no formulation, pentostatin, EHNA or 8-SPT.

FIG. 5 graphically compares levels of TNF in liver and in spleen from non-septic animals and septic animals treated with no formulation, 8-SPT or pentostatin.

FIG. 6 shows the 24 hour levels of thiobarbituric acid reactive substances from the jejeunum in non-septic animals and in septic animals treated with no formulation, with 8-SPT or with pentostatin.

FIG. 7 graphically illustrates vascular resistance and change in resistance in hepato-splanchnic systems of septic and non-septic animals treated with saline, a vehicle, or 8-PTH.

FIG. 8 graphically illustrates vascular resistance and change in resistance in skeletal muscles of non-septic and septic animals treated with saline, a vehicle, and 8-PTH.

FIG. 9 graphically illustrates vascular resistance and change in resistance in brains of non-septic and septic animals treated with saline, a vehicle, or 8-PTH.

FIG. 10 shows (A) 2'-deoxy-2'-fluorocoformycin, and (B) shows 2'-deoxy-8-epi-2'-fluorocoformycin. Both of these compounds have high enzyme-inhibitory activities against adenosine deaminase.

FIG. 11 shows erythrohydroxynonyl adenine (EHNA).

~~FIG. 12 shows a general chemical structure of (2S,3R)-3(6-aminopurin-9-yl)arylkan-2-ols (also called 9-aralkyladenines, or ARADS)~~

FIG. 13 shows serum concentrations of (A) TNF- α ; (B) IL-6; and (C) soluble TNF Receptors I and II in rats 24 hours after induction of sham (non-SIRS), fluid-resuscitated SIRS (SIRS), and SIRS treated with pentostatin 2 hours after induction (SIRS + pentostatin). SIRS was induced secondary to sepsis by ip introduction of 400

090492-112901

Subt
B1

mg/kg cecal matter in 5 ml/kg D₅W. At 2 hours after SIRS induction, rats received 50 ml/kg 0.9% normal saline iv (SIRS group), or 1 mg/kg pentostatin followed by fluids, as described.

FIG. 14 shows concentrations of IL-10 in (A) serum; (B) livers; and (C) spleens; from rats 24 hours after induction of sham (non-SIRS), fluid-resuscitated SIRS (SIRS), and SIRS treated with pentostatin 2 hours after induction (SIRS + pentostatin). SIRS was induced secondary to sepsis by ip introduction of 400 mg/kg cecal matter in 5 ml/kg D₅W. At 2 hours after SIRS induction, rats received 50 ml/kg 0.9% normal saline iv (SIRS group), or 1 mg/kg pentostatin followed by fluids, as described.

FIG. 15 shows survival (percent alive) up to 6 days after SIRS induction secondary to sepsis in the absence (untreated; closed circles) or presence of ADA inhibition with pentostatin (1 mg/kg). Pentostatin was administered prior to (pre-Rx; closed squares) or 2 hours after (2 hr pst Rx; closed triangles) SIRS induction. All rats received 50 ml/kg 0.9% normal saline iv 2 hours after SIRS induction.

FIG. 16 shows serum concentrations of (A) TNF- α ; (B) IL-10 in the spleen; and (C) serum IL-1beta in rats 2 hours after intraperitoneal injection of *E coli* endotoxin, and the effects of various treatment doses with pentostatin.

DETAILED DESCRIPTION OF THE INVENTION

Conditions resulting with or from inflammatory response syndrome (SIRS) are associated with exaggerated immune responses, oxygen free radical-mediated injury, and tissue perfusion maldistribution. Adenosine is a ubiquitous molecule that modulates immune function, can suppress or increase free-radical production, and produces localized vasodilation. *In vitro*, adenosine is capable of suppressing macrophage activation and limiting cytokine release. Adenosine also attenuates neutrophil adherence and production of reactive oxygen radical moieties by neutrophils.

Adenosine becomes an important vasoactive mediator in sepsis. The majority of the evidence regarding adenosine's immuno-modulating role comes from *in vitro* studies. These cannot be easily extrapolated to the *in vivo* immune response associated with sepsis. Thus, the claim that the ability to amplify endogenous adenosine's capabilities to perform these functions *in vivo* during sepsis by inhibiting adenosine deaminase comes from experiments disclosed herein. One of the advantages of altering adenosine concentrations *in vivo* by manipulating the adenosine metabolic pathways is that it would

5

Adenosine as an important vasoactive mediator in sepsis

15

20

25

30

inflammatory responses. IL-10 and IL-6 are modulated by adenosine *in vitro* (LeMoine *et al.*, 1996; Hosko *et al.*, 1996; and Ritchie, *et al.*, 1997) and *in vivo* in the present examples.

Endogenous adenosine modulates oxyradical damage during sepsis

5 Three pathways have been demonstrated to be involved in oxygen free radical production during sepsis: the arachidonic acid pathway (via cyclo-oxygenase), neutrophil activation and degranulation, and from adenosine catabolites via xanthine oxidase (Schiller *et al.* 1993). Allopurinol, a specific inhibitor of xanthine oxidase, protects the bowel from hypoperfusion and increased intestinal permeability caused by endotoxin, 10 indicating a significant role for xanthine oxidase-mediated damage (Xu *et al.*, 1993; Castillo *et al.*, 1991) reported significantly better survival using allopurinol in their rodent model of cecal ligation and puncture. In addition, rat hepatic sequestered neutrophils produce superoxides after *in vivo* endotoxin infusion (Spitzer *et al.*, 1994). These studies suggest that oxygen free radical-mediated hepato-splanchnic damage 15 occurs after a septic challenge, and that both neutrophil and xanthine oxidase pathways of production are involved.

Adenosine has also been shown to inhibit a variety of neutrophil functions, including adherence, TNF-stimulated lactoferrin secretion and H₂O₂ production. Both adenosine, and the adenosine A2 receptor agonist, NECA, inhibit neutrophil adherence 20 and H₂O₂ production, while N6-phenylisopropyladenosine, and A1 receptor agonist, actually promote neutrophil adherence.

Oxygen free radical injury, characteristic of sepsis, could also be a result of adenosine accumulation. The fate of adenosine that enters the xanthine oxidase pathway has been explored extensively in the heart. While adenosine can be active as a 25 vasodilator under conditions of hypoperfusion, its half-life is extremely short, as it is rapidly taken up by other cells, particularly vascular endothelium (Becker *et al.* 1987). During constant perfusion of rat hearts with a hypoxic solution, Becker and Gerlach demonstrated elevations in coronary venous effluent uric acid, accounting for up to 73% of the total amount of purine in the venous effluent. Allopurinol (10nM) reduced uric 30 acid production to below detectable levels, confirming that the source of the uric acid was the xanthine oxidase pathway. While hypoxanthine levels increased modestly, there was little other evidence of substrate backup, and radiotracer experiments showed reduction

0949212301
"E264660"

in cellular purine release. Thus, it appears that under hypoxic perfused conditions, adenosine can provide substantial substrate through the xanthine oxidase pathway. In a model of coronary ischemia and reperfusion, inhibition of adenosine deaminase with erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) significantly reduces the amount of adenosine capable of entering the xanthine oxidase pathway, resulting in improved functional recovery from ischemia, reduction of the concentrations of adenosine catabolites, and greater increases in tissue ATP concentrations after reperfusion, an important consideration when increasing endogenous adenosine levels using an adenosine deaminase inhibitor. This treatment method blocks the entry of adenosine into the xanthine oxidase pathway, but allows endogenous adenosine to re-enter the cell for rephosphorylation by adenosine kinase. In contrast, inhibition of adenosine kinase can be used to increase interstitial adenosine concentrations, but this approach allows the increased endogenous adenosine to enter the xanthine oxidase pathway (resulting in increased oxygen free radicals by this pathway) and prevents adenosine from being used in nucleotide salvage. Inhibition of adenosine deaminase is effective in reducing oxygen free radical-mediated damage during sepsis. This mode of elevating endogenous adenosine is likely to be particularly effective in sepsis, wherein both localized oxygen supply-dependent perfusion imbalances and neutrophil activation can be deleterious.

The model of sepsis used herein is associated with elevated serum concentrations of TNF- α as early as 30 minutes after sepsis induction, and these concentrations remain elevated up to 72 hours (FIG. 2). TNF- α was also elevated at 24 and 72 hours in samples of liver and spleen in septic rats (FIG. 3). The surgical procedure (non-septic controls) used to induce sepsis also resulted in elevation of TNF- α in these tissues at 24 hours, but these were significantly lower than in the septic rats. The animals clearly demonstrate other indicators of progressive sepsis (progressive leukocytosis, lactacidemia) through day 7. These data demonstrate that 24-72 hours of sepsis in the present invention is an appropriate time frame in which to examine the ability of adenosine to modulate TNF- α *in vivo*.

Studies were conducted to determine if manipulation of adenosine-mediated events would result in alterations in the TNF- α response in this model. At the time of sepsis induction, rats were treated in one of four ways. One group received only 0.9% normal saline as a vehicle control (No R_x; n=6). A second group were treated with the

0994923 11301
0327 224650

adenosine deaminase inhibitor, pentostatin (5 mg/kg/12 hours ip; n=5), to prevent enzymatic degradation of endogenous adenosine. The third group received the adenosine deaminase inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; 1 μ mole/kg + 1 μ mole/kg/hr; iv; n=3). A fourth group received the adenosine receptor antagonist 8-sulphophenyltheophylline (SPT; 400 μ g/kg/8 hours; n=5). Results are shown in FIG. 4. In the No R_x septic group, sepsis resulted in elevated serum TNF- α at 4 and 24 hours, similar to that seen in FIG. 2. Inhibition of adenosine deaminase with either pentostatin or EHNA resulted in attenuation of this response at both 4 and 24 hours after sepsis induction. SPT amplified the response at 24 hours, but not at 4 hours. Similar responses were seen in liver and spleen TNF- α concentrations (FIG. 5). The results indicate that preventing endogenous adenosine degradation diminishes the *in vivo* TNF- α response to sepsis, while blockade of adenosine receptors amplifies this response. These data are consistent with the hypothesis that manipulating endogenous adenosine during sepsis can be used to effectively modulate serum TNF- α concentrations. In neither the adenosine deaminase inhibition nor the 8-SPT groups were blood pressures or heart rates significantly different from saline-treated septic rats. Importantly, chronic adenosine deaminase inhibition did not result in exacerbation of hypotension associated with sepsis. In addition, it is noteworthy that 3 of the 5 saline-treated septic rats survived to day 3, while 4 of the 5 septic rats treated with pentostatin survived to 3 days post-sepsis, and only 2 of the 5 treated with 8-SPT survived. An interpretation of these data suggest that endogenous adenosine plays an important role in sepsis, and that inhibition of adenosine deaminase can exert beneficial effects via modulation of the immune response.

It is increasingly apparent that feedback between pro and anti-inflammatory processes is critically important to the clinical outcome from SIRS, as taught by Bone (Bone, 1996). The balance between complementary pro-and anti-inflammatory molecules is typified by TNF α and its soluble receptors, sTNF types I and II. The ability of ADA inhibition to restore balance to these complimentary molecules in the SIRS responses was tested with a more clinically relevant addition of fluid resuscitated sepsis. ADA was inhibited using 1 mg/kg pentostatin 2 hours after induction, when the SIRS imbalance had already manifested. The imbalance between these molecules in response to sepsis-induced SIRS is shown in FIG. 13. Serum TNF- α and IL-6 were significantly elevated in septic animals compared to controls (127.7 ± 26.5 pg/ml, n=10 vs. 35.8 ± 16.7

pg/ml, n=15 for TNF- α and 11968 ± 3853 pg/ml, n=8 vs. 573 ± 86 pg/ml, n=15 for IL-6). Treatment of septic animals with the ADA inhibitor pentostatin significantly attenuated the rise in both TNF- α and IL-6 (20.3 ± 14.8 pg/ml, n=11 and 5525 ± 1435 pg/ml, n=11 respectively) (see FIGS. 13(A) and 13(B)). Circulating levels of soluble TNF receptors I and II (sTNFR I or p55 and sTNFR II or p75) were significantly increased in septic animals compared to non-septic controls (4629 ± 765 pg/ml, n=11 vs. 1292 ± 223 pg/ml, n=16 for p55 and 23759 ± 3277 pg/ml, n=9 vs. 4748 ± 596 pg/ml, n=12 for p75). Pentostatin-treated septic animals had significantly decreased levels sTNFR II, but no significant change in sTNFR I (16525 ± 1226 pg/ml, n=12 and 4624 ± 404 pg/ml, n=18 respectively) (see FIG. 13(C)). Further evidence of a complex, modulatory mode of action is indicated by IL-10 concentrations in the liver and spleen. While serum concentrations of this anti-inflammatory molecule are unaffected by pentostatin treatment after administration of LPS (FIG. 14(A)), the concentrations found in the liver and spleen are elevated (FIG. 14(B) and 14(C)).

Bemelmans *et al.* teaches that blockade of TNF- α with any one of three anti-TNF antibodies results in increased serum concentrations of sTNF receptors after LPS challenge in mice. A recent randomized trial in humans utilizing sTNFR-fusion protein (Fisher *et al.*, 1996) actually made the outcome from sepsis worse in a dose-dependent fashion. As such, the contribution of such imbalances to clinical outcomes must be considered. In considering data disclosed herein from such a vantage, it is interesting to note that the effects of inhibiting ADA on both TNF- α and its receptors indicate beneficial effects on the balanced response. Not only was there an attenuation of the pro-inflammatory cytokine, TNF- α , but also a diminution of circulating sTNFR II. Even the lack of change in sTNFR I after pentostatin treatment suggests an influence, because simple attenuation of TNF- α would be expected to cause an increase in sTNFR I, as taught by Bemelmans *et al.* In addition, the present results demonstrate a survival benefit of this treatment approach in SIRS (FIG. 15). The present invention demonstrates that inhibition of adenosine deaminase suppresses both the pro-inflammatory molecule, one of its soluble receptors, and prevents the rebound increases in either soluble receptors normally associated with anti-inflammatory therapy, while increasing localized tissue concentrations of another anti-inflammatory molecule (IL-10). Thus, the inflammatory

response is not merely suppressed, but beneficially modulated in a unique, novel, and complex fashion.

Oxidative Tissue Damage

Concentrations of the products of lipid peroxidation [thiobarbituric acid reactive substances (TBARS)] were measured using the thiobarbituric acid reaction from representative samples of jejunum tissue of septic and control rats at 24 and 72 hours after sepsis induction. Tissue homogenate samples (0.2 ml; 10% w/v) were combined with 0.2 ml 8.1% sodium dodecyl sulfate, 1.5 ml of 20% acetic acid (the solution adjusted to pH 3.5 with NaOH), and 1.5 ml of 0.8% aqueous solution of thiobarbituric acid. Distilled water was added to bring the total volume up to 4 ml, then heated in an oil bath at 950°C for 60 min. After cooling, 1 ml distilled water and 5 ml n-butanol/pyridine (15:1 v/v) was added. After shaking 30 sec. followed by centrifugation at 4000 rpm for 10 min, absorbance of the organic layer was measured at 532 nM. Data from tissue obtained from non-septic rats, and septic rats treated with saline (No Rx), 8-SPT, or pentostatin are expressed as nmols TBARS per mg protein in FIG. 6. Elevated TBARS were found as early as 24 hours after sepsis induction. Adenosine receptor blockade (8-SPT) resulted in exacerbation of the sepsis-induced elevation in TBARS. Inhibition of adenosine deaminase with pentostatin resulted in diminution of tissue TBARS during sepsis. These data confirm the presence of oxidative damage in this model of sepsis, and the ability to reduce oxidative damage by inhibiting adenosine deaminase. The data demonstrating exacerbation of oxidative damage with adenosine receptor blockade points to the primary role for endogenous adenosine in these responses.

Effective Inhibition of Adenosine Deaminase

To achieve these effects, inhibition of adenosine deaminase can be up to 100 percent to be effective in treating SIRS without concern for immune suppression. Inhibition of up to 100% can be maintained for no more than 3 consecutive days, after which ADA activity should be allowed to return to at least 50% of baseline values before another dose of the inhibitor can be given. Adenosine deaminase activity in the jejunum of untreated rats (38.4 units per μ g protein) was suppressed > 99 percent (to 2.34 units per μ g protein) within two hours of a single injection of 1 mg/kg 2-deoxycofomycin. This dose was effective in reducing mortality in this model (FIG. 15). Concerns of

immunosuppression as a side effect were unwarranted, as jejunal adenosine deaminase activity returned to as much as 35.9 units per μg protein by 24 hours after the administration of 2-deoxycofomycin. The dose required to achieve up to 100 percent inhibition of adenosine deaminase can be readily determined in each patient. One-two hours after administration of a starting dose of the inhibitor, adenosine deaminase activity can be measured in various bodily fluids, tissues, dialysates, or cells by spectrophotometric methods according to the method of Vielh and Castellazzi, or other appropriate measurement that provides information regarding ADA enzyme activity. Measurement of adenosine deaminase activity can also be used to monitor the return of ADA activity after therapeutic inhibition for the treatment or prevention of SIRS.

The optimal inhibition of ADA at greater than 99%, as described above, can be seen in FIG. 16 which shows that the maximal effect of pentostatin on modulating cytokine concentrations in response to 2 mg/kg LPS (endotoxin) occurred at 1 mg/kg dose of pentostatin. As described above, this dose results in >99% inhibition of ADA activity. Lower doses than this were unable to consistently suppress TNF- α and IL-1beta with concomittant stimulation of the anti-inflammatory cytokine, IL-10. However, at 1mg/kg, when ADA activity was inhibited >99% , a balanced response optimal for treating SIRS was demonstrated.

Evidence of adenosine involvement in altered perfusion in sepsis/SIRS

Systemic vascular responses were examined 24 hours after induction of sepsis in the presence or absence of adenosine receptor blockade in septic and non-septic rats using radiolabelled microspheres. For these experiments, the surgical procedure involving vascular access was modified to include a catheter in the left ventricle of the heart (via the carotid artery), and a catheter in the tail artery (Intramedic PE-50, Baxter) to permit reference blood withdrawal and blood pressure monitoring. Regional blood flows were determined using radiolabelled microspheres. The microspheres (15 μM New England Nuclear, Boston), labeled with one of four isotopes (^{46}Sc , ^{85}Sr , ^{95}Nb , ^{141}Ce), were mixed in 0.9% normal saline with 0.01 % Tween-80 added to prevent aggregation. The microspheres were adjusted to provide a minimum of 400 microspheres per tissue sample, and represented approximately 100,000-250,000 spheres per injection. The specific isotopes and their order of injection were randomized in each experiment, with each injection representing a volume of 0.4 ml/injectate. The microspheres were

The microspheres were injected into the LV (to ensure adequate mixing) at a constant rate over 15 seconds, and the catheter slowly flushed with 0.9% NSal. Right and left renal and testicular blood flows were compared in each animal to confirm uniform distribution of the microspheres. Tissues collected at necropsy for this study included the hepatosplanchnic organs (liver, spleen, pancreas, colon, stomach, cecum, and small intestine), epididymal adipose tissue, skeletal muscle (from the rectus and hind limb), testes, and kidneys. Wet weights were obtained and all tissues were counted in a gamma spectrophotometer (Beckman 9000). Gamma activity in the injectate vials was counted prior to the experiments. Actual injected amounts for each isotope were calculated by subtracting any isotope counts remaining in the vials, syringes, and catheters used for injection. Cardiac output (CO) was determined by dividing the total injectate counts for any given isotope by the counts in the reference sample and multiplying by the fixed withdrawal rate of the reference sample. The results for cardiac output are expressed as ml/min. Tissue counts attributed to each isotope were determined after subtracting the overlap of energy spectra from higher energy isotopes (Compton back-scatter). Individual tissue blood flows were determined by dividing the counts obtained in the tissue by the reference withdrawal counts and multiplying by the reference withdrawal rate. Tissue blood flows were then normalized to wet weight was calculated by adding the individual tissue blood flows of the stomach, small intestine, cecum, colon, pancreas, hepatic artery and spleen, and dividing by the liver weight. Regional tissue vascular resistances were calculated from regional blood flows and arterial blood pressure, according to the equation:

Regional vascular resistance = mean arterial blood pressure / regional blood flow.

Twenty-four hours after sepsis induction, hepato-splanchnic, skeletal muscle, and adipose blood flows were significantly higher than in non-septic rats. The administration of the non-selective adenosine antagonist, 8-phenyltheophylline (8-PTH), caused increases in total hepato-splanchnic (FIG. 7), skeletal muscle (FIG. 8), and brain vascular resistances (FIG. 9) in septic rats, but not in non-septic rats. The use of 8-PTH required

a special vehicle (30 mM NaOH, 8.5% ethyl alcohol, and 0.1 M NaCl.), which had no effect in either septic or non-septic rats. The use of 8-SPT had similar effects as 8-PTH, with the exception of changes in cerebral vascular resistance, owing to the inability of 8-SPT to cross the blood-brain barrier. These data demonstrate that endogenous adenosine is important in maintaining lower resting vascular tone in skeletal muscle and hepato-splanchnic circulations during sepsis. Based on the similar ability of 8-SPT to block the salutary effects of adenosine on immune and oxyradical-mediated responses during sepsis, and the beneficial effects of inhibiting adenosine deaminase relative to these responses, it is reasonable to speculate that inhibition of adenosine deaminase would result in greater reductions in hepato-splanchnic, muscle, and cerebral vascular resistances during sepsis, resulting in elevated blood flows to these regions.

Reduction in capillary leakage

Examination of untreated septic rats, and septic rats treated with the adenosine deaminase inhibitor, pentostatin, or the adenosine receptor antagonist, 8-SPT, revealed the following findings. The peritoneal cavity of the untreated septic rats contained between 2-3 ml of sero-sanguinous fluid. This volume was increased to 3-5 ml in septic rats treated with 8-SPT. In pentostatin-treated septic rats, there was 0-1 ml of serous fluid (free of red cells). Untreated septic rats also demonstrated evidence of small bowel hemorrhage, and the lumen of sporadic, 3-4 cm segments of the small bowel were distended with fluid. In septic rats treated with 8-SPT, small bowel hemorrhaging was evident, and the entire small bowel was dusky in appearance. The entire length of the small bowel, and much of the cecum and colon, was distended with fluid, and the animals experienced bloody diarrhea. In septic rats treated with pentostatin, there was little to no evidence of small bowel hemorrhage, and the lumen contents appeared normal, including formed stool in the colon. This evidence is consistent with problems associated with capillary leakage and fluid exudation during untreated sepsis, exacerbation of capillary leakage upon treatment with 8-SPT, and amelioration of capillary leakage upon treatment with pentostatin.

Formulations

For the purposes of this invention, the compounds of the invention may be administered by a variety of means including orally, parenterally, by inhalation spray, sublingually, topically, or rectally in formulations containing conventional non-toxic

pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes sub-cutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques. Intraarterial and intravenous injection as used herein includes administration through catheters. Preferred for certain indications are
5 methods of administration which allow rapid access to the tissue or organ being treated, such as intravenous injections. When an organ outside a body is being treated, perfusion is preferred.

Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration.

10 The pharmaceutical compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art.

The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated, the particular
15 mode of administration, and the active ingredient used.

It will be understood that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs which have previously been
20 administered; and the severity of the particular disease undergoing therapy, as is well understood by those skilled in the art.

Examples of use of the method of the invention includes the following. It will be understood that these examples are exemplary and that the method of the invention is not limited solely to these examples.

25 The method may be used in septic patients in whom oral administration is counter-indicated, as is well understood by those skilled in the art. The compound would be given as a sterile injectable preparation intravenously, for example, as a suspension of solution formulated according to the known art suitable for the active ingredient.

MATERIALS AND METHODS

30 ENHA (FIG. 11)

Erythrohydroxynonyl adenine (ENHA) was discovered by Schaeffer *et al.* (1974). A difference between EHNA and pentostatin is the potency of inhibition of the enzyme.

0394923 112801
102211 E264660

EHNA has a K_i value of 10^{-9} M which makes it one thousand times less active than pentostatin. Another major difference between the two drugs is their duration of inhibition of ADA. Unlike pentostatin, inhibition with EHNA is reversible with a half life of half an hour. This difference is based on the fact that the EHNA is apparently
5 metabolized by liver enzymes to oxidized (hydrolyzed) metabolites which are excreted in the urine (McConnell *et al.*, 1983).

ARADS (FIG. 12)

ARADS are (2S,3R)-3(6-Aminopurin-9-yl)arylkan-2-ols (also called 9-aralkyl-adenines), where the alkyl group is composed of 4-8 carbon atoms having a hydroxyl
10 group at carbon #2 with (S) chirality and an adenine ring attached through the nitrogen at position #9 to carbon #3 with (R) chirality. The terminal carbon of this alkyl chain is attached to an aromatic ring (phenyl, naphthyl, thienyl, furanyl, etc.) which ring can be substituted with alkyl, halide, hydroxy, carboxylic acid, ester, ether, azide, amine, and other moieties to make useful analogs. These are a novel class of adenine derivatives
15 which have been shown to inhibit the enzyme adenosine deaminase at therapeutically useful levels. The relevant inhibitory constant (K_i) values are in the range of 10^{-7} - 10^{-10} M. These compounds with potencies in this range can reversibly inhibit ADA in an effective manner, without permanently deactivating the enzyme. ADA inhibitors that have similar biological profiles have been shown to be of therapeutic value when used to protect heart
20 muscle against ischemic damage.

Model of SIRS/sepsis

All of the studies on the effects of adenosine deaminase inhibitors were performed in a model of chronic peritoneal sepsis developed by the inventors that results in systemic inflammatory response syndrome (SIRS). Sepsis was induced under pentobarbital
25 anesthesia (50 mg/kg) in each rat by intraperitoneal (ip) injection of 200 mg/kg rat cecal contents mixed as a slurry in 5% dextrose in water (D5W). The cecal slurry was prepared from fresh cecal contents of a donor rat and was used within two hour of collection to induce sepsis. Non-septic controls received an equivalent volume ip injection of D5W. Polyethylene catheters (Intramedic PE-50, Baxter) were inserted into the right internal
30 jugular vein and right carotid artery. The jugular catheter was used for venous access (drug infusions; volume replacement, etc). The carotid catheter was used to obtain arterial blood samples, and to monitor arterial blood pressure and heart rate. The

catheters were secured in their respective vessels, tunneled subcutaneously to exit in the interscapular region, and filled with heparinized saline (50 units/ml 0.9% normal saline). Incisions were closed in layers using 3-0 silk. Rats were allowed to recover from anesthetic and provided food and water ad libitum.

5 TNF- α is modulated by adenosine deaminase inhibition

Serum and tissue tumor necrosis factor- α (TNF- α) concentrations were determined by enzyme-linked immunosorbant assay. Samples of serum, liver, and spleen were collected, rapidly weighed, and frozen in liquid nitrogen. On the day of assay, tissues are added to labeled tubes containing lysis buffer (volume = 10 ml/gram
10 wt. with 1:10 dilution) and kept on ice. The lysis buffer is 20 mM Tris (pH 7.4) containing 170 I/ml phenylmethylsulfonylflouride (PMSF), 0.5 g/ml leupeptin, 0.7 g/ml pepstatin, and 2.0 g/ml aprotinin to inhibit proteases. Samples were immediately homogenized using five 3 sec bursts, washing grinding pistol (3x) between samples with phosphate buffered saline. Samples are then centrifuged for 20 min at 2200 RPM, 4°C.
15 The supernatant was removed and used for TNF- α measurements. Briefly, each microplate well contained 50 μ l of assay diluent. To each well, 50 μ l of standard, control, or serum/homogenate supernatant sample were added and mixed on an orbital plate shaker. Plates were incubated at room temperature for 2 hours. Each well was then aspirated and washed with wash buffer 4 times. After final aspiration of wash buffer,
20 100 μ l of rat TNF- α conjugate was added to each well. Wells were then covered and incubated for 2 hours at room temperature. At the end of the incubation, the aspiration/wash procedure was repeated 4 times, after which 100 μ l of stabilized chromogen solution was added to each well. Next, plates were incubated for 45 minutes at room temperature in a dark area. After this final incubation period, 100 μ l stopping
25 solution was added to each well. Optical density of each well at 450 nM was determined within 30 minutes using a Biotek Instruments EL312e microtiter plate reader. Concentrations of TNF- α were calculated from the standard curves.

EXAMPLES

The following examples illustrate some of the embodiments of the invention:

5
10

15
20
25
30

Example 2: Manipulation of Endogenous Adenosine Modulates Serum Tumor Necrosis Factor- α (TNF- α) During Sepsis in Rats.

Endogenous adenosine (ADO) is known to modulate macrophage TNF- α production *in vitro*. During sepsis, endogenous ADO plays a significant role in determining resting vascular resistance in selected regions *in vivo*. Manipulation of endogenous ADO during sepsis modulates serum TNF- α concentration *in vivo*, as follows:

Male SD rats (350-400 g) were made septic by IP introduction of a 200 mg/kg cecal slurry. At the time of sepsis induction rats were treated with the ADO deaminase inhibitor pentostatin (PNT; n=5), the ADO receptor antagonist 8-sulfo-phenyltheophylline (SPT; n=5), or vehicle (VEH; 0.9% NaCl; n=6). TNF- α (pg/ml) was determined at 4 and 24 hours after sepsis induction by ELISA. Significant differences from the VEH treated group over time ($p \leq 0.05$) were determined by 2-way ANOVA followed by the Tukey test.

In the VEH group, sepsis resulted in elevated TNF- α at 4 (934 ± 453) and 24 hours (1287 ± 437). PNT resulted in attenuation of this response at both 4 and 24 hours after sepsis induction (592 ± 62 and 671 ± 175 , respectively). SPT amplified the response at 24 hours (2479 ± 875), but not at 4 hours (1167 ± 428).

The results indicate that preventing endogenous ADO degradation with PNT diminishes the *in vivo* TNF- α response to sepsis, while blockade of ADO receptors amplifies this response. These data suggest that manipulating endogenous adenosine during sepsis can be used to effectively modulate rather than completely ablate the TNF- α response to sepsis. Modification of adenosine pathways is a useful tool in the management of sepsis.

DOCUMENTS CITED

- Abd-Elfattah, A.S., M.E. Jessen, S.A. Hanan, G. Tuchy, A.S. Wechsler, *Circ.* 82 (5 Suppl), IV341 (1990).
- Abraham, E. *et al.*, *Lancet* 351, 929 (1998).
- 5 Adamik, B., M. Zimecki, A. Waszczyk, and A. Kübler, *Arch. Immunol. Ther. Exp.* (Warsz) 45, 169 (1997).
- Amiot, F., C. Fitting, K.J. Tracey, J.M. Cavaillon, F. Dautry, *Mol. Med.* 3, 864 (1997).
- Arvidsson, S., K. Fält, U. Haglund, *Acta Chir. Scand.* 156, 215 (1990).
- 10 Barankiewicz, J., A. Cohen, *Eur. J. Immunol.* 15, 627 (1985).
- Becker, B.F., E. Gerlach, Topics and Perspectives in Adenosine Research, E. Gerlach and B.F. Becker, Eds. (Springer-Verlag, Berlin; Heidelberg, 1987), p. 209.
- Belardinelli *et al.*, *Prog. in Cardiovasc. Diseases*, 1989, 32:73-97.
- Bemelmans, M. H., D. J. Gouma, and W. A. Buurman. 1993. LPS-induced sTNF-
15 receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. *J Immunol* 151(10):5554-62.
- Bone, R. C. Sir Isaac Newton, sepsis, SIRS, and CARS 1996. *Crit Care Med.* 24:1125-1128.
- Broner, C.W. *et al.*, *Circ.Shock* 29, 77 (1989).
- 20 Casey, L.C., R.A. Balk, R.C. Bone, *Annals of Int. Med.* 119, 771 (1993).
- Castillo, M., L.H. Toledo-Pereyra, R. Gutierrez, D. Prough, E. Shapiro, *Amer. Surg.* 57, 313 (1991).
- Cohen, J., J. Carlet, *Crit.Care Med.* 24, 1431 (1996).
- Cronstein, B.N., *et al.*, *J. Immunol.* 148, 2201 (1992).
- 25 Cronstein, B.N., D. Naime, G. Firestein, *Arthritis and Rheumatism* 38, 1040 (1995).
- Cronstein *et al.*, *J. Clin. Invest.*, 1986, 78:760-770.
- Eigler, A., *et al.*, *Scand.J.Immunol.* 45, 132 (1997).
- Firestein *et al.*, *J.Immunol.*; 152, 5853-5859.
- 30 Fisher, C. J., Jr., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. Schein, and E. Benjamin. 1996. Treatment of septic shock with the

00446660
"E222T" 00446660

- tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. *N Engl J Med* 334(26):1697-702.
- Gruber WO/94/17809 (Gensia, Inc.).
- Haskó, G. *et al.*, *J.Immunol.* 157, 4634 (1996).
- 5 Itoh, K., T. Majima , K. Edo, M. Mizugaki, N. Ishida, *Tohoku J.Exp.Med.* 157, 205 (1989).
- Kato, T., *et al.*, *Antimicrob.Agents Chemother.* 39, 1336 (1995).
- Leff, J.A., *et al.*, *Lancet* 341, 777 (1993).
- LeMoine, O., *et al.*, *J. Immunol.* 156, 4408 (1996).
- 10 McConnell *et al.*, *CBA Mice Biochem. Pharmacol.*, 1983.
- Meduri, G.U., *et al.*, *Chest* 107, 1062 (1995).
- Morgan, R.A., *et al.*, *Circ. Shock* 25, 319 (1988).
- Moser *et al.*, *Am. J. Physiol.*, 1989, 256: C799-C806.
- Motew, S.J., M.G. Mourelatos, R.N. Miller, J.L. Ferguson, W.R. Law, *Shock* 7,
- 15 439 (1997).
- Motew, S.J., *et al.*, *J. Surg. Res.* 80, 326 (1998).
- Parmely *et al.*, *FASEB Journal*, 1991, 5: A 1602.
- Peralta, J.G., *et al.*, *Circ. Shock* 39, 153 (1993).
- Riches, D.W.H., J.L. Watkins, P.M. Hensen, D.R. Stanworth, *J. Leukocyte Biol.*
- 20 37, 545 (1985).
- Richter, J., *J. Leukocyte Biol.* 51, 270 (1992).
- Ritchie, P.K., *et al.*, *Cytokine* 9, 187 (1997).
- Schaeffer, H.J. and C.F. Schwender, *J. Med. Chem.*, 17:68, 1974.
- Schiller, H.J., P.M. Reilly, G.B. Bulkley, *Crit. Care Med.* 21, S92 (1993).
- 25 Schrader, in *Regulatory Function of Adenosine*, Berne *et al.* eds., pp. 133-156, 1983.
- Schrier *et al.*, *J. Immunol.*, 1990, 145:1874-1879.
- Spitzer, J.A., P. Zhang, A.A. Mayer, *J. Leukocyte Biol.* (1994). 56: 166-173.
- U.S. Patent No. 5,646,128; Firestein *et al.*; July 8, 1997: Method for Treating
- 30 Adenosine Kinase Related Conditions.
- U.S. Patent No. 5,643,035; French *et al.*; October 31, 1995: Process for Purifying Pentostatin.

Vielh, P., and Castellazzi, M. 1984. A colorimetric assay for serial determination of adenosine deaminase activity in small lymphocyte populations. *J. Immunolog. Methods* 73: 313-320.

Walley, K.R., N.W. Lukacs, T.J. Standiford, R.M. Strieter, S.L. Kunkel, *Infect. Immun.* 64, 4733 (1996).

Xu, D., *et al.*, *J. Trauma* 34, 676 (1993).

Zager, R.A., *Circ. Res.* 68, 185 (1991).

20250422 14:30